LifeSigns launches smart ward with wireless patient monitoring technology
Amala Hospital partners with LifeSigns to provide revolutionary technology for the first time in the State
Amala Hospital partners with LifeSigns to provide revolutionary technology for the first time in the State
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Twelve hospitals across India will be part of the network which will support the trial in India
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Subscribe To Our Newsletter & Stay Updated